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BIOMARKERS
Changes in Total IgE Plasma Concentration Measured at the Third Month
during Anti-IgE Treatment Predict Future Exacerbation Rates in
Difficult-to-Treat Atopic Asthma: A Pilot Study
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In severe, difficult-to-treat atopic asthma with sensitization to perennial allergens, monoclonal antibodies directed against immunoglobulin
E (IgE) are recognized to be clinically effective. Omalizumab, a recombinant monoclonal antibody, selectively binds to the high-affinity
C-epsilon 3 site of human IgE and inhibits the inflammatory cascade in response to antigenic stimuli. Currently, no indicator is available
for predicting patients’ responsiveness to long-term omalizumab treatment. This study aims to assess the relationship between early changes
in plasma IgE concentration and major outcome variables over a 12-month course of omalizumab. Methods. Twenty-three nonsmoking, severe
asthmatics (14 females; mean age 47.3 years ± 12.0 SD; mean BMI 25.8 kg/m2 ± 9.6 SD) sensitized to perennial allergens and unresponsive
to high doses of common therapies were evaluated during a 12-month period of omalizumab treatment. Variables included total IgE plasma
concentrations, Forced Expiratory Volume 1 second (FEV1) symptom complaints (Asthma Control Test (ACT) score), number of emergency
visits, hospitalizations, and exacerbations. The Wilcoxon signed-rank test was used to compare changes observed after the 1-year omalizumab
treatment versus baseline. Statistical modelization was used to determine possible relationships between changes in outcomes after 12 months
and early changes in plasma IgE (after 3 months of treatment). Results. The number of emergency visits, hospitalizations, and exacerbations
decreased (p < .004, p < .001, and p < .001, respectively) over the 12-months. In contrast, FEV1 and ACT score substantially increased (both
p < .001); the ACT score reaching maximum after only 3 months. The S model showed the best fit and proved the strict relationship between
the increase in IgE after 3 months and the exacerbation rate over the 1-year survey (threshold value of ≥250 IU/ml, p < .001). The improvement
in FEV1 was independent of the increase in IgE. Conclusions. When confirmed on a larger population, early changes in IgE may be used as a
predictor of future responders to omalizumab in terms of exacerbation rate, thus minimizing the economic burden of anti-IgE therapy.
Keywords anti-IgE, difficult-to-treat atopic asthma, omalizumab, perennial allergens, predictive model, severe bronchial asthma
INTRODUCTION
Asthma is a chronic inflammatory disease which is
still highly prevalent, with an estimated 300 million
patients (1) affected by this disease worldwide. In
Italy, the prevalence of this disease is estimated as
7% for the general population (2). In contrast to the
vast majority of cases which respond effectively to
inhaled (ICS) (or systemic) corticosteroids (CS) and/or
bronchodilators, asthma does not respond satisfactorily to
normal therapeutic regimes in 5–10% of patients, even
when drugs are administered appropriately and at their
highest doses (3).
In severe, difficult-to-treat atopic asthma with sen-
sitization to perennial allergens, monoclonal antibodies
directed against immunoglobulin E (IgE) have shown to
be clinically effective (4).
Omalizumab is a recombinant monoclonal antibody
which selectively binds to the high-affinity C-epsilon 3
site of human IgE. This drug mechanism prevents IgE
from binding to mast cells and other effector cells, thus
∗Corresponding author: Claudio Micheletto, MD, Lung Department,
Orlandi General Hospital, Bussolengo, Verona, Italy; E-mail: cmicheletto@
ulss22.ven.it
leading to the inhibition of the inflammatory cascade in
response to antigenic stimuli.
Several studies performed on patients with moderate-
to-severe allergic asthma have shown the clinical efficacy
of anti-IgE treatment in addition to standard therapy (ICS
+ long-acting beta agonists; LABA) and demonstrated
a significant reduction in annual exacerbation rates
and severity of respiratory symptoms, together with an
increase in FEV1 values and quality-of-life scores (5–12)
In general terms, the efficacy of omalizumab has been
demonstrated in children, adolescents, and adults for
doses able to guarantee at least 0.016 mg/kg/IU/ml of IgE
for a minimum of 4 weeks (13).
Due to the binding of the monoclonal antibody
to human IgE, plasma concentrations of total IgE
usually tend to increase progressively during omalizumab
treatment. However, this increase does not occur to the
same extent in all asthma patients, this variability likely
being dependent on their response to anti-IgE treatment
in terms of circulating free IgE.
At present no indicator is available for predicting
patient responsiveness to prolonged omalizumab treat-
ment, in terms of both lung function and major clinical
outcomes.
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The aim of this study was to examine the presence of a
possible relationship between early changes in plasma IgE
concentration and variation in major clinical outcomes
over the 1 year of omalizumab treatment.
MATERIALS AND METHODS
Twenty-three nonsmoking severe atopic asthmatics (14
females; mean age 47.3 years ± 12.0 SD; range 29–69
years; mean BMI 25.8 kg/m2 ± 9.6 SD) sensitized to
perennial allergens and unresponsive to high doses of
respiratory drugs (such as daily long acting broncodilators
agents (LABA) + inhaled corticosteroids (ICS) and
leukotrienes (LTs) antagonists, slow acting bronchodila-
tors agents (SABA) prn, and frequent courses of oral
CS) were evaluated every month over a 12-month period
of omalizumab treatment (dose range 150–450 mg). The
following variables were monitored: total IgE plasma
concentration, FEV1, symptom complaints by means of
the ACT score (14, 15), and number of emergency visits,
hospitalizations, and exacerbations. Exacerbations were
defined as events of asthma impairment requiring a sub-
stantial implementation of regular daily treatment (mainly
with systemic steroids) or leading to hospitalization.
Total plasma IgE concentration was measured by
means of a solid phase, chemiluminescent immunometric
assay (Immulite® System, Diagnostic Product Corp., Los
Angeles, CA, USA) and expressed in IU/ml.
Lung function was assessed by a spirometric test
(Masterscreen, Vyasis-Jaeger, Hoechberg, Germany) and
performed after a 24 h wash-out period from any
respiratory drug. FEV1 was expressed as % predicted
(Comunità Europea Carbone Acciaio (CECA) 1993, in
the range 18–70 years) (16).
Procedures adopted for omalizumab prescription,
administration, and monitoring were in strict agreement
with guidelines according to the National Ministry of
Health (17). This study was approved by the local Ethical
Committee (prot. n.1489, approved on 19 January 2010).
Descriptive Statistics
The Wilcoxon signed-rank test was used to compare
changes observed for each variable after 12 months
of omalizumab treatment versus baseline since it was
regarded as the most reliable test for nonparametric com-
parisons between dependent variables without Gaussian
distribution (verified by the Shapiro–Wilk test); p < .05
was considered statistically significant.
Statistical Modelization
Potential relationships existing between changes in IgE
and the main long-term clinical outcomes (such as FEV1,
the ACT score, and number of exacerbations, emergency
or unscheduled visits, and hospitalizations) were assessed
by testing several statistical models.
Our aim was to determine the best statistical model
that was capable of effectively describing the potential
relationship between changes in long-term outcomes
(after a 12-month course of omalizumab), the dependent
variable (Y), and early changes in total plasma IgE
concentration (measured after the first 3 months of
omalizumab treatment), the independent variable (X).
Of the models used (such as linear, logarithmic,
inverse, quadratic, cubic, S, compound, power, growth,
exponential), the most fitting one was found to be the S
model (18):
y = eb0+ b1x
Differences measured from baseline (t0) plasma IgE
concentration (or FEV1) after 3 months of treatment
(t3m) (variable X) are related to corresponding changes in
long-term outcomes (such as FEV1, the ACT score, and
number of emergency visits, hospitalizations, and exacer-
bations over the 12 months) (variable Y) and described
by the formula reported above. Since parameters b0
and b1 of the S model are unknown, their values were
estimated from data measured from patient samples. The
significance level was fixed at 5%.
Statistical analysis was performed using SPSS soft-
ware version 18 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Patient demographic characteristics and outcome mea-
sures during the anti-IgE treatment period are reported in
Table 1. Statistical differences between t0 and t12 are also
shown.
All variables were shown to be significantly improved
after the 12-month course of omalizubam (Table 1).
Moreover, the number of emergency visits, hospital-
izations, and exacerbations dropped substantially after
TABLE 1.—Patient clinical and demographic characteristics.
t0 t1 t2 t3 t12 P-value
IgE (IU/ml) 246.7 ± 180.5 385.2 ± 312.0 606.4 ± 495.6 598.1 ± 521.9 601.4 ± 557.2
IgE (IU/ml) – +138.5 ± 166.4 +359.7 ± 369.2 +351.5 ± 408.6 359.6 ± 411.4
FEV1 (% predicted) 57.1 ± 14.4 78.3 ± 19.9 77.1 ± 25.0 .001
ACT score 11.9 ± 3.1 19.1 ± 4.3 20.3 ± 4.3 .001
Visits (n) 0.6 ± 0.8 0.0 ± 0.0 .004
Hospitalizations (n) 0.9 ± 0.6 0.0 ± 0.0 .001
Exacerbations (n) 2.1 ± 1.1 0.5 ± 0.7 .001
Note: Data presented as mean values ± SD at the different experimental times, and p-values of comparisons (t0–t12).
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1 year of treatment (p < .004, p < .001, and p < .001,
respectively), while FEV1 increased substantially over
the same period (p < .001). With regard to changes in
respiratory signs, the ACT score reached its maximum
value (indicating improvement) at the third month of
treatment (p < .001) and did not show any further
significant improvement over the remaining 9 months
(p = .16) (Table 1).
Trends in all variables were also compared by gender,
and no statistical difference was observed.
Modelization
Results of the S model are reported in Table 2. In addition,
the report for parameter estimates for b0 (the constant of
the model) and b1 (the functional coefficient for X) is
presented in the final two columns of Table 2.
Only changes in the number of exacerbations and
FEV1 were entered into the modelization, since the
number of all other discrete variables was too small.
The peculiar sigmoid shape of the identified function
shows that the stabilization of the exacerbation rate
can be achieved when the mean variation of total IgE
plasma concentration measured at the third month of
omalizumab treatment is ≥250 IU/ml. Moreover, the
model was shown to be highly statistically significant
(p < .001), with an adjusted square coefficient of 0.525.
This implies that only when the variation in total IgE
plasma concentration measured at the end of the first 3
months of treatment is≥250 IU/ml, a significant inversion
of the exacerbation trend is predictable for the patient
(Figure 1).
The same methodological approach was applied to
examine the presence of a relationship between changes
in IgE concentration after 3 months and FEV1 variation
observed after 1 year of treatment (variable Y).
Data reported in Table 3 indicate that in this case no
model was able to identify any significant relationship
between X and Y variables, suggesting that variations
in FEV1 are independent of variations in total plasma
IgE concentration (Figure 2). Furthermore, the model
characterized by the lowest p-value was referred to as the
“power model” (p= .109), even if the corresponding level
of significance was not found to be statistically acceptable
and figures obtained discourage any further attempt of
modelization.
DISCUSSION
Despite the fact that severe asthma is characterized by
a low rate of prevalence, this disease still places a
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FIGURE 1.—Graphic representation of the relationship identified by the S
model between changes in total IgE plasma concentrations obtained after
3 months (X variable) and changes in n. exacerbations after 12 months of
omalizumab (Y variable).
substantial strain on health-care resources (19). Since a
significant proportion of patients suffering from severe
asthma still do not receive effective treatment, the
interest in developing new therapeutic approaches that are
targeted toward the control of severe asthma is constantly
increasing. Current research is therefore mainly oriented
toward the optimization of long-term clinical and
economic outcomes in difficult-to-treat asthma.
The biologic treatment of severe persistent atopic
asthma that is uncontrolled with usual highly dosed
respiratory drugs has been in clinical use since 2006.
omalizumab is a humanized monoclonal antibody that
selectively binds to the high-affinity C-epsilon 3 site
of human IgEs, thus blocking the cascade of biological
events leading to the pronounced clinical expression of
bronchial asthma (12, 20, 21).
Several studies carried out on severe atopic asthmatics
sensitized to perennial allergens have clearly demon-
strated the efficacy of omalizumab in terms of a signif-
icant reduction in the frequency of moderate-to-severe
exacerbations, emergency visits, hospitalization rate, use
or systemic steroids, and respiratory symptoms, with an
improved quality of life and reduced health-care costs
(6–11, 22, 23). Other studies have also shown that
omalizumab is extremely well tolerated (24, 25). More-
over, data from a pharmacoeconomic study conducted
over a 12-month period that was specifically designed
to more closely reflect the real-life setting further
TABLE 2.—Summary of the S model and the parameter estimates.
Summary of the model Parameter estimates
Equation R2 F DF1 DF2 Significance Constant b1
S 0.525 19.876 1 18 .000 3.057 −35.961
Notes: The dependent variable is “number of exacerbations at the 12th month.” The independent variable is “the change in plasma total IgE concentration measured at the
third month.”
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TABLE 3.—Summary of all models and the parameter estimates.
Summary of the model Parameter estimates
Equation R2 F DF1 DF2 Significance Constant b1 b2 b3
Linear 0.040 0.750 1 18 .398 19.685 0.007
Logarithmic 0.106 2.145 1 18 .160 −4.978 5.033
Inverse 0.082 1.606 1 18 .221 26.793 −670.379
Quadratic 0.220 2.398 2 17 .121 10.273 0.064 −3.82E−005
Cubic 0.232 1.610 3 16 .226 6.920 0.095 −9.63E−005 2.58E−008
Compound 0.077 1.509 1 18 .235 14.411 1.001
Power 0.136 2.835 1 18 .109 3.594 0.291
S 0.078 1.524 1 18 .233 3.080 −33.442
Growth 0.077 1.509 1 18 .235 2.668 0.001
Exponential 0.077 1.509 1 18 .235 14.411 0.001
Notes: The dependent variable is “FEV1 changes at the 12th month of treatment.” The independent variable is “the change in plasma total IgE concentration measured at the third
month.”
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FIGURE 2.—Graphic representation of all models used for investigating any possible relationship between changes in total IgE plasma concentrations after
3 months (X variable) and changes in FEV1% prediction after 12 months of omalizumab (Y variable).
confirmed that long-term treatment with omalizumab
reduced exacerbations by 59% in uncontrolled severe
asthma, previously therapeutically optimized (10).
However, even though clinical (e.g., lung function,
quality of life) and economic outcomes definitively
confirm the clinical efficacy and the cost-effectiveness of
omalizumab treatment, to our knowledge no indicator is
currently available that is capable of predicting a patient’s
response to long-term anti-IgE therapy.
Since anti-IgE therapy can demonstrate variable
efficacy in severe uncontrolled asthma, we thought this
specific aspect warranted further investigation. As with
any biological strategy, initial health-care costs may
be incurred (sometimes over several months) before
demonstrating therapeutic value in real life (absolute
cost-effectiveness in these cases). With this in mind, our
clinical and economic interest was focused on gener-
ating a predictive algorithm capable of discriminating
responders from nonresponders to long-term omalizumab
treatment, in the shortest possible time.
Data from this study, besides further confirming
the therapeutic value of a 1-year anti-IgE therapeutic
approach in real life, have shown that a substantial
clinical response to treatment can be expected in severe
uncontrolled asthma patients, when the increase in their
total IgE plasma concentration is at least 250 IU/ml after
only 3 months of omalizumab therapy.
This finding was found to be highly statistically sig-
nificant and correlated very tightly with the concomitant
drop in exacerbation rate monitored over the 12-month
period. In contrast, the change in lung function over the
year (i.e., FEV1) was not associated with an increase in
IgE concentration, thus suggesting a clear independence
between these two clinical long-term outcomes. As the
improvement in FEV1 reaches its maximum after 3
months of treatment, the consequent clinical implication
is that changes in FEV1 over time do not represent a
reliable indicator for evaluating the long-term efficacy of
anti-IgE therapy.
Data derived from this study support the hypothesis
that the absolute increase in IgE of ≥250 IU/ml from
baseline after only 3 months of anti-IgE treatment is
independent of the original total plasma concentration.
This could be used as a sensitive and reliable predictive
index of future long-term clinical responsiveness to
omalizumab in clinical practice.
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The possibility of discriminating responders from
nonresponders in only a few weeks, in terms of their
future exacerbation rate, also provides the advantage of
minimizing the economic impact of anti-IgE adminis-
tration, which would otherwise have been delivered for
several months further, prior to establishing its clinical
benefit.
Another clinical implication emerging from these
data is that respiratory symptoms (such as ACT score)
ameliorate rapidly and significantly over the first few
months of treatment in responder patients, without any
further significant improvement in the remaining months.
This time-course closely paralleled that of the increase in
IgE concentration.
CONCLUSIONS
When confirmed on larger samples of patients, this
novel predictive index should serve to update the
present pharmacoeconomic indices which characterize
the cost-effectiveness of the anti-IgE therapy (such as
the gained Quality Adjusted Life Years (QALY) and
the Incremental Cost Effectiveness Ratio (ICER) value).
These indices, which are already regarded as quite
convenient for a long-term biological treatment (10),
would be further optimized and much more closely
represent conditions in real life.
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